Here, we hypothesized that modulating the plasmatic levels of 5-HT through a tryptophan-rich diet we could inhibit prostatic growth.
INTRODUCTION AND OBJECTIVES:
Although benign prostatic hyperplasia is one of the most prevalent human diseases, its etiology remains unknown. Recent studies described how serotonin (5-HT) inhibits benign prostatic growth through modulation of the androgen receptor in the presence of Testosterone. The aims of this work were to determine the role of Testosterone in plasmatic and prostatic serotoninergic system.
METHODS: C57BL/6 mice were submitted to surgical castration and divided into 3 Groups, Group 1: supplemented with vehicle; Group 2 and 3 supplemented with different Testosterone concentrations, during 14 days. Prostatic and Plasmatic 5-HT concentrations were determined in different time points.
RESULTS: Normal mice prostate exhibits high levels of 5-HT. The total amount of prostatic 5-HT seems not to be regulated by the presence or absence of androgens (Fig.1) . Plasmatic 5-HT concentration significantly increases after castration (Fig.2) and Testosterone supplementation strongly decreases Plasmatic 5-HT concentration (Fig.3) .
CONCLUSIONS: We showed for the first time that the normal mice prostate produces, independently of androgens, high levels of 5-HT. This prostatic 5-HT might counteracts the stimulatory action of Testosterone in prostatic growth. The finding that androgens strongly regulate plasmatic 5-HT raises the question of a possible relationship between extra-prostatic organs and the regulation of prostatic growth.
Benign prostatic hyperplasia (BPH) is mainly caused by increased prostatic volume and smooth muscle (SM) tone. Non-muscle myosin II (NMM II) and SM myosin II (SMM II) play important roles in mediating cell growth and SM tone. Blebbistatin (BLEB, a small, cell permeable molecule which inhibits NMM II) has been recently suggested to inhibit SM contraction. The aim of this study is to investigate the effect of blebbistatin on regulating contractility and growth of prostate cells and to provide insight into possible mechanisms associated with these actions.
METHODS: BPH-1 (human epithelia cell line) and WPMY-1 (human stroma cell line) cells were utilized for in vitro studies. For in vivo studies, 2-weeks of BLEB treatment was administered by direct injection to the rat prostate. Cell growth was determined by flow cytometry analysis and in vitro organ bath studies were performed to explore contractility of rat prostate. SMM isoforms, including SM myosin heavy chain (MHC) isoforms (SM1/2 and SM-A/B) and myosin light chain 17 isoforms (LC 17a/b ), isoform ratios were determined via competitive RT-PCR. SM MHC, NM MHC isoforms (NMMHC-A and NMMHC-B) and proteins related to cell apoptosis and cell cycle were further analyzed via Western blotting and Masson's trichrome staining was used to determine epithelium, SM and collagen content.
RESULTS: In vitro experiments displayed that BLEB could dose-dependently trigger apoptosis and retard the growth of BPH-1 and WPMY-1. Consistent with this in vitro effect, administration of BLEB to the prostate could decrease rat prostatic epithelia and SM cells via increased apoptosis. Western blotting confirmed the effects of BLEB on inducing apoptosis through a mechanism involving MLC 20 dephosphorylation with downregulation of Bcl-2 and upregulation of BAX and cleaved caspase 3. Meanwhile, NMMHC-A and NMMHC-B, the downstream proteins of MLC 20 , were found significantly attenuated in BPH-1 and WPMY-1 cells, as well as rat prostate tissues. In addition, in vivo experiments also demonstrated that BLEB not only decreased SM cells and SM MHC expression, but also lessened phenylephrine (PE) induced contractile force and altered prostate SMM II isoform composition, with upregulation of SM-B and downregulation of LC 17a , favoring a faster contraction.
CONCLUSIONS: Our novel data demonstrated that BLEB regulates myosin II expression and functional activity in vivo and in vitro. Thus, our study indicated that BLEB not only decreased prostate size (static component) but also changed the prostatic SM tone (dynamic component). 
MP45-11 NEW STRATEGIES FOR INHIBITION OF NON-ADRENERGIC PROSTATE SMOOTH MUSCLE CONTRACTION BY PHARMACOLOGIC INTERVENTION
Qingfeng Yu*, Christian Gratzke, Paul Kuppermann, Annika Herlemann, Yiming Wang, Frank Strittmatter, Raphaela Waidelich, Christian Stief, Martin Hennenberg, Munich, Germany INTRODUCTION AND OBJECTIVES: Inhibition of prostate smooth muscle contraction by a1-adrenoceptor antagonists (a1-blockers) is the first option for medical treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). In fact, increased prostate smooth muscle tone may drive urethral obstruction and LUTS. However, the efficacy of a1-blockers is limited to 50%, because non-adrenergic mediators including endothelin-1 and thromboxane A2 (TXA2) increase prostate smooth muscle tension in parallel to a1-adrenoceptors and may therefore keep urethral obstruction despite therapy with a1-blockers. Consequently, future options with highest efficacy need to target a1-adrenergic and non-adrenergic contractions at once. Recently, several compounds have been reported to inhibit adrenergic prostate contraction, but their effects on non-adrenergic contraction are still unknown. Here, we examined effects of RacGTPase inhibitors and of a Src family kinase (SFK) inhibitor on nonadrenergic prostate contractions.
METHODS: Prostate tissues were obtained from radical prostatectomy. Contractions were studied in an organ bath, where they were induced by the a1-adrenoceptor agonist methoxamine, the TXA2 analog U46619, or by endothelin-1.
RESULTS: Methoxamine, U46619, and endothelin-1 induced concentration-dependent contractions of prostate strips. Inhibitory effects of the Rac inhibitors EHT1864 (100 mM) and NSC23766 (100 mM) and of the SFK inhibitor AZM475721 (10 mM) on a1-adrenergic contraction were confirmed by inhibition of methoxamine-induced contractions by all three inhibitors. EHT1864 caused significant inhibition of endothelin-1-and U46619-induced contractions, which was observed at 0.1-3 mM of endothelin-1 (p<0.001 between EHT1864 and control group), and at 1-30 mM of U46619 (p<0.001 between EHT1864 and control group). NSC23766 caused significant inhibition of U46619-induced contractions, which was observed at 3-10 mM of U46619 (p<0.001 between NSC23766 and control group). NSC23766 did not change endothelin-1-induced contractions. AZM475721 did not change U46619-or endothelin-1-induced contractions.
CONCLUSIONS: From the three examined inhibitors, EHT1864 is the most promising from a translational view, as it inhibited TXA2-and endothelin-1-induced besides a1-adrenergic prostate contractions. This reflects divergent pharmacologic profiles of EHT1864 and NSC23766,
